Aaron Brody1, Tahsin Rahman1, Brian Reed1, Scott Millis1,2, Brian Ference3,4, John M Flack4,5, Phillip D Levy1,5. 1. Department of Emergency Medicine, Wayne State University School of Medicine, Detroit, MI. 2. Department of Physical Medicine and Rehabilitation, Wayne State University School of Medicine, Detroit, MI. 3. Division of Cardiovascular Medicine, Wayne State University School of Medicine, Detroit, MI. 4. Division of Translational Research and Clinical Epidemiology and Department of Medicine, Wayne State University School of Medicine, Detroit, MI. 5. Cardiovascular Research Institute, Wayne State University School of Medicine, Detroit, MI.
Abstract
BACKGROUND: Poor blood pressure (BP) control is a primary risk factor for target organ damage in the heart, brain, and kidney. Uncontrolled hypertension is common among emergency department (ED) patients, particularly in underresourced settings, but it is unclear what role ED providers should play in the management of chronic antihypertensive therapy. OBJECTIVES: The objective was to evaluate the safety and efficacy of prescribing antihypertensive therapy from the ED. METHODS: This was a retrospective study of data pooled from two prospective, longitudinal, randomized controlled trials, both of which enrolled ED patients with asymptomatic hypertension. Antihypertensives were prescribed at emergency physician discretion, and this was not related to randomization arm. Demographic data, BP at screening and randomization visit, and data on adverse effects potentially related to antihypertensive therapy were compiled. Means were compared using Student's t-tests, and proportions were compared using chi-square tests. The effect of antihypertensive therapy on BP control was further analyzed using multivariable regression modeling controlling for age, race, sex, hypertension history, study cohort, and ED BP. RESULTS: Data were abstracted for 217 subjects. The median interval from ED visit to randomization was 12 days. Seventy-six subjects (35%) received one or more prescriptions for antihypertensive therapy. Age, sex, race, hypertension history, and mean duration of hypertension were equivalent between groups. Although mean ED BP was higher among those who received prescriptions, the mean systolic BP (sBP) reduction from ED to randomization was significantly greater (difference = 19 mm Hg, 95% confidence interval = 12 to 26 mm Hg). No patient in either group had an sBP less than 100 mm Hg at randomization. On multiple regression modeling, randomization sBP reduction was independently associated with antihypertensive prescription (p = 0.001). The incidence of adverse effects was equivalent and low in both groups. No new neurological deficits, ischemic events, or life-threatening anaphylactic reactions were reported in either group. CONCLUSIONS: Prescription of antihypertensive medication from the ED is associated with significantly lower sBP at short-term outpatient follow-up. Antihypertensive therapy was not associated with an increased incidence of adverse events, and BP reduction did not exceed potentially harmful levels. Initiation of chronic antihypertensive therapy in the ED is safe and effective and may be a reasonable consideration for at-risk populations.
BACKGROUND: Poor blood pressure (BP) control is a primary risk factor for target organ damage in the heart, brain, and kidney. Uncontrolled hypertension is common among emergency department (ED) patients, particularly in underresourced settings, but it is unclear what role ED providers should play in the management of chronic antihypertensive therapy. OBJECTIVES: The objective was to evaluate the safety and efficacy of prescribing antihypertensive therapy from the ED. METHODS: This was a retrospective study of data pooled from two prospective, longitudinal, randomized controlled trials, both of which enrolled ED patients with asymptomatic hypertension. Antihypertensives were prescribed at emergency physician discretion, and this was not related to randomization arm. Demographic data, BP at screening and randomization visit, and data on adverse effects potentially related to antihypertensive therapy were compiled. Means were compared using Student's t-tests, and proportions were compared using chi-square tests. The effect of antihypertensive therapy on BP control was further analyzed using multivariable regression modeling controlling for age, race, sex, hypertension history, study cohort, and ED BP. RESULTS: Data were abstracted for 217 subjects. The median interval from ED visit to randomization was 12 days. Seventy-six subjects (35%) received one or more prescriptions for antihypertensive therapy. Age, sex, race, hypertension history, and mean duration of hypertension were equivalent between groups. Although mean ED BP was higher among those who received prescriptions, the mean systolic BP (sBP) reduction from ED to randomization was significantly greater (difference = 19 mm Hg, 95% confidence interval = 12 to 26 mm Hg). No patient in either group had an sBP less than 100 mm Hg at randomization. On multiple regression modeling, randomization sBP reduction was independently associated with antihypertensive prescription (p = 0.001). The incidence of adverse effects was equivalent and low in both groups. No new neurological deficits, ischemic events, or life-threatening anaphylactic reactions were reported in either group. CONCLUSIONS: Prescription of antihypertensive medication from the ED is associated with significantly lower sBP at short-term outpatient follow-up. Antihypertensive therapy was not associated with an increased incidence of adverse events, and BP reduction did not exceed potentially harmful levels. Initiation of chronic antihypertensive therapy in the ED is safe and effective and may be a reasonable consideration for at-risk populations.
Authors: Alan S Go; Dariush Mozaffarian; Véronique L Roger; Emelia J Benjamin; Jarett D Berry; Michael J Blaha; Shifan Dai; Earl S Ford; Caroline S Fox; Sheila Franco; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Mark D Huffman; Suzanne E Judd; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Rachel H Mackey; David J Magid; Gregory M Marcus; Ariane Marelli; David B Matchar; Darren K McGuire; Emile R Mohler; Claudia S Moy; Michael E Mussolino; Robert W Neumar; Graham Nichol; Dilip K Pandey; Nina P Paynter; Matthew J Reeves; Paul D Sorlie; Joel Stein; Amytis Towfighi; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner Journal: Circulation Date: 2013-12-18 Impact factor: 29.690
Authors: Alan S Go; Mary Ann Bauman; Sallyann M Coleman King; Gregg C Fonarow; Willie Lawrence; Kim A Williams; Eduardo Sanchez Journal: Hypertension Date: 2013-11-15 Impact factor: 10.190
Authors: Jeffrey A Cutler; Paul D Sorlie; Michael Wolz; Thomas Thom; Larry E Fields; Edward J Roccella Journal: Hypertension Date: 2008-10-13 Impact factor: 10.190
Authors: J D Neaton; R H Grimm; R J Prineas; J Stamler; G A Grandits; P J Elmer; J A Cutler; J M Flack; J A Schoenberger; R McDonald Journal: JAMA Date: 1993-08-11 Impact factor: 56.272
Authors: Brigitte M Baumann; David M Cline; John J Cienki; Darcy Egging; Jill F Lehrmann; Paula Tanabe Journal: Am J Hypertens Date: 2009-03-05 Impact factor: 2.689
Authors: Phillip D Levy; Robina Josiah Willock; Michael Burla; Aaron Brody; James Mahn; Alexander Marinica; Samar A Nasser; John M Flack Journal: J Am Soc Hypertens Date: 2016-10-28
Authors: Elizabeth A Samuels; Gail D'Onofrio; Kristen Huntley; Scott Levin; Jeremiah D Schuur; Gavin Bart; Kathryn Hawk; Betty Tai; Cynthia I Campbell; Arjun K Venkatesh Journal: Ann Emerg Med Date: 2018-10-11 Impact factor: 5.721
Authors: Brittany Stewart; Aaron Brody; Abhinav C Krishnan; Sara K Brown; Phillip D Levy Journal: Curr Hypertens Rep Date: 2019-06-19 Impact factor: 5.369
Authors: Candace D McNaughton; Wesley H Self; Yuwei Zhu; Alexander T Janke; Alan B Storrow; Phillip Levy Journal: Am J Cardiol Date: 2015-09-10 Impact factor: 2.778